A Phase 3 interventional study of Tradipitant and Placebo in Motion Sickness, sponsored by Vanda Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Motion Sickness with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Motion Sickness · United States.
Among the 28 studies in Motion Sickness with a site in United States, this one is the 3rd largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2021, is one of 10 in phase 3, and was the 13th registered.
50 studies on the registry are indexed under Motion Sickness; 9 are open to participants now.
Browse Motion Sickness studies →4 of the 28 studies in Motion Sickness with a site in United States are open now. Recruiting first, the newest first:
59th Medical Wing · Sites in United States
Ages 18–50 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 21–70 · Healthy volunteers
Repurposed Therapeutics, Inc. · Sites in United States
Ages 18–65 · Healthy volunteers
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Motion Sickness studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; none take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 12
First in 2006; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 366 is above the median of 59 across 44 interventional studies indexed under Motion Sickness.
Median enrollment 63 across the 27 interventional studies, 59 across the 1 observational. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 28 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 4 studies filed under Motion Sickness — fewer than ten, so there is no comparison to draw.
2 of the studies in Motion Sickness with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06138613Phase 3Vanda PharmaceuticalsMotion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | 2027-09-30 |
| NCT05622344Johns Hopkins UniversityStableEyes With Active Neurofeedback | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Motion Sickness with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tradipitant
Drug: Tradipitant
Drug: Placebo
Oral Capsule
Oral Capsule
Prevention of Vomiting Measured by Vomiting Assessment (VA)
Prevention of vomiting measured by Vomiting Assessment (VA) score in tradipitant high dose. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited. The Count of Participants indicates participants who vomited.
Time frame: 1 day
| Milestone | Tradipitant High Dose | Tradipitant Low Dose | Placebo |
|---|---|---|---|
| Started | 121 | 123 | 122 |
| Completed | 120 | 123 | 122 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
Prevention of vomiting measured by Vomiting Assessment (VA) score in tradipitant high dose. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited. The Count of Participants indicates participants who vomited.
| Participants | Tradipitant High Dose | Tradipitant Low Dose | Placebo |
|---|---|---|---|
| Prevention of Vomiting Measured by Vomiting Assessment (VA) | 22 | 24 | 54 |
Collected over Adverse Events were recorded from time of randomization until the end of study visit, up to 7 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tradipitant High Dose | 0/120 (0%) | 0/120 (0%) | 26/120 (21.7%) |
| Tradipitant Low Dose | 0/123 (0%) | 0/123 (0%) | 20/123 (16.3%) |
| Placebo | 0/122 (0%) | 0/122 (0%) | 4/122 (3.3%) |
| Event | Tradipitant High Dose | Tradipitant Low Dose | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 10/120 | 7/123 | 3/122 |
| SomnolenceNervous system disorders | 10/120 | 8/123 | 1/122 |
| FatigueGeneral disorders | 10/120 | 5/123 | 0/122 |
| Age, Continuous(years) | Tradipitant High Dose | Tradipitant Low Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 47.7 ± 14.84 | 49.6 ± 14.40 | 48.6 ± 13.48 | 48.6 ± 14.23 |
| Sex: Female, Male(Participants) | Tradipitant High Dose | Tradipitant Low Dose | Placebo | Total |
|---|---|---|---|---|
| Female | 87 | 82 | 75 | 244 |
| Male | 34 | 41 | 47 | 122 |
| Ethnicity (NIH/OMB)(Participants) | Tradipitant High Dose | Tradipitant Low Dose | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 14 | 12 | 14 | 40 |
| Not Hispanic or Latino | 99 | 102 | 105 | 306 |
| Unknown or Not Reported | 8 | 9 | 3 | 20 |
| Race/Ethnicity, Customized(Participants) | Tradipitant High Dose | Tradipitant Low Dose | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 2 | 3 |
| Asian | 7 | 9 | 11 | 27 |
| Black or African American | 10 | 5 | 5 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| White | 103 | 105 | 102 | 310 |
| Other | 0 | 3 | 2 | 5 |
| Region of Enrollment(participants) | Tradipitant High Dose | Tradipitant Low Dose | Placebo | Total |
|---|---|---|---|---|
| United States | 121 | 123 | 122 | 366 |
| Body Mass Index (BMI)(kg/m^2) | Tradipitant High Dose | Tradipitant Low Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 26.785 ± 4.6327 | 27.299 ± 4.9265 | 28.037 ± 5.1835 | 27.377 ± 4.9342 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Apr 2023, 16 months.
Results were first posted in Dec 2024, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tradipitant